| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/13/2001 | WO2001032647A3 Benz`f!indoles for use in the treatment of 5ht receptor related disorders |
| 12/13/2001 | WO2001032184A3 Abc1 modulation for the modulation of cholesterol transport |
| 12/13/2001 | WO2001029017A3 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF η-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |
| 12/13/2001 | WO2001026637A3 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
| 12/13/2001 | WO2001025219A3 Piperazine compounds |
| 12/13/2001 | WO2001021157A3 Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
| 12/13/2001 | WO2001021008A3 Method for increasing pet activity |
| 12/13/2001 | WO2001020026A3 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 12/13/2001 | WO2001019399A3 Method of potentiating chemotherapy and treating solid tumors |
| 12/13/2001 | WO2001019376A3 METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS |
| 12/13/2001 | WO2001019362A3 Formulations for treating or preventing mucositis |
| 12/13/2001 | WO2001018181A3 Enzyme inhibitors |
| 12/13/2001 | WO2001012192A3 Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil |
| 12/13/2001 | WO2001011038A3 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 12/13/2001 | WO2000069390A3 Compositions for improving bioavailability of orally administered drugs |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000033857A9 Cancer treatment composition and method using natural plant essential oils |
| 12/13/2001 | WO2000032773A9 Compositions and methods for increasing bone mineralization |
| 12/13/2001 | WO2000032179A3 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells |
| 12/13/2001 | WO2000029008A9 Hiv-specific t-cell induction |
| 12/13/2001 | WO2000015845A9 T-type calcium channel |
| 12/13/2001 | US20010051760 Use of photofrin as a radiosensitizer |
| 12/13/2001 | US20010051735 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance |
| 12/13/2001 | US20010051722 Aminoaryl Oxazolidinone N-oxides |
| 12/13/2001 | US20010051660 Method for reducing oxalate |
| 12/13/2001 | US20010051659 Non-fermented osmotic laxative and method for treating and preventing colorectal cancers |
| 12/13/2001 | US20010051658 Method and use of penicillamines and other alpha-amino-beta,beta-mercapto-beta,beta-dimethyl-ethane derivatives as dicarbonyl scavengers for treatment of conditions resulting from protein, lipid, and DNA damage |
| 12/13/2001 | US20010051657 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 12/13/2001 | US20010051656 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 12/13/2001 | US20010051654 Administering to the multiple sclerosis patient an agent selected from the group consisting of proteasome inhibitor, ubiquitin pathway inhibitors, agents that interfere with activationof NF-Kappa B via ubiquitin proteasome pathway |
| 12/13/2001 | US20010051653 Method for improving disturbancies of activities of daily living after stroke |
| 12/13/2001 | US20010051652 Administering a therapeutically effective amount of melatonin to a patient suffering from paralysis of the extremities caused by cerebral infarction |
| 12/13/2001 | US20010051651 Administering effective amount of 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivative to the patient for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation |
| 12/13/2001 | US20010051650 Topical compositions comprising ascomycins |
| 12/13/2001 | US20010051648 Administering to a mammal for the treatment of dry eye or other disorders requiring the wetting of the eye a heteroatom such as nitrogen, oxygen or sulfur interrupted hydroxyeicosatetraenoic acid related compounds |
| 12/13/2001 | US20010051647 A compressed tablet of antibacterial oxazolidinone selected from the group consisting of linezolid, eperezolid and (S)-N-((3-(3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl-2-o xo-5-oxazolidinylmethyl)acetamide S,S-dioxide |
| 12/13/2001 | US20010051646 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/13/2001 | US20010051644 Methods of stimulating the immune system |
| 12/13/2001 | US20010051642 Administering to the Alzheimer's patient an effective amount of farnesyl transferase inhibitor compounds such as dihydro naphthalenones |
| 12/13/2001 | US20010051640 C7 carbamoyloxy substituted taxanes |
| 12/13/2001 | US20010051638 Ethanol solvate of (-)-cis-2- (2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl} -4H-1-benzopyran-4-one |
| 12/13/2001 | US20010051636 Combination treatment for inhibiting bone loss |
| 12/13/2001 | US20010051635 Inhibits the cyclin-dependent kinase subunit of P-TEFb (positive transcription elongation factor b) required for HIV propagation and replication in human cells; low dosages; side effects reduction; AIDS |
| 12/13/2001 | US20010051632 Histamine H3 receptor antagonists; central nervous system disorders; Alzheimer's disease; antiepileptic agents; eating disorders; motion sickness; attention deficit hyperactivity disorder; cognition activators; schizophrenia |
| 12/13/2001 | US20010051628 Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors |
| 12/13/2001 | US20010051626 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 12/13/2001 | US20010051624 Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| 12/13/2001 | US20010051623 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic |
| 12/13/2001 | US20010051622 5HT2C Receptor agonists to treat schizophrenia and central nervous system disorders; obsessive-compulsive disorder; antidepressants, migraine; sleep disorders; eating disorders; obesity; antidiabetic, -epileptic and anxiolytic agents |
| 12/13/2001 | US20010051619 E.g., ethyl 3-(4-(2-(3-oxo-2H-1,4-benzoxazin-4-yl)ethoxy)-phenyl-2-ethoxypropenoate where 1,4-benzothiazine or quinoxaline can be substituted for the benzoxazine ring; anticholesterol, diabetic agents; obesity; hyperlimpidemia |
| 12/13/2001 | US20010051618 Treating diseases including poriomania or hyperkinesia by suppressing non-intentional locomotion without suppressing intentional locomotion; gamma-aminobutyric acid receptor agonists; attention deficit disorder |
| 12/13/2001 | US20010051616 Administering alendronate sodium |
| 12/13/2001 | US20010051615 Angina therapy |
| 12/13/2001 | US20010051613 Water solubility |
| 12/13/2001 | US20010051611 Supplying protein, antibodies, ribozymes |
| 12/13/2001 | US20010051609 Administering Dna |
| 12/13/2001 | US20010051607 Treatment of hereditary diseases with gentamicin |
| 12/13/2001 | US20010051602 Alzheimer's disease; adjust apolipoprotein concentration |
| 12/13/2001 | US20010051599 Anticancer agents, central nervous system disorders, Alzheimer's disease |
| 12/13/2001 | US20010051595 Injection into blood |
| 12/13/2001 | US20010051368 Methods of inhibiting the effects of amyloidogenic proteins |
| 12/13/2001 | US20010051274 Antifouling compounds and uses thereof |
| 12/13/2001 | US20010051206 Comprises fatty acids from flaxseed oil which provide less immunosuppression than fatty acids derived from fish sources |
| 12/13/2001 | US20010051191 Bioflavonoid (quercetin) mixed with protelytic digestive enzyme protease (bromelin and papain), also containing cranberry; for treatment of urinary tract infections |
| 12/13/2001 | US20010051185 Osmotic device containing ranitidine and a prokinetic agent |
| 12/13/2001 | US20010051184 Alcohol solubility |
| 12/13/2001 | US20010051181 Novel formulations for the transdermal administration of asimadoline |
| 12/13/2001 | US20010051179 Preventing infectious microorganisms from spreading from open sores or wounds comprising applying to the wounda quantitiy of cyanoacrylate sufficient to cover and seal the open wound or sore |
| 12/13/2001 | US20010051172 Cinnamic acid or derivatives chosen from mono- and polyhydroxycinnamic acids, alcohols, aldehydes, esters etc. show an effect on lipid synthesis; promote moisturization of the skin; reinforce suppleness of the skin |
| 12/13/2001 | US20010051170 Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter |
| 12/13/2001 | US20010051169 Halogenated alkylnyl carbamate and a saturated or unsaturated acylic, cyclic polyol or polyol ether for the treatment of inflammatory and/or desquamating skin disorders associated with Malassezia species; antidandruff agent |
| 12/13/2001 | US20010051166 Hydroxide-releasing agents as skin permeation enhancers |
| 12/13/2001 | US20010051164 An alimentary adjuvant for veterinary use intended to increase fertilization yields in animal breeding includes atleast one saturated monoglyceride (fish liver oil), which improves the fertilization power of the stored sperm |
| 12/13/2001 | US20010051160 Satisfy composition and method of weight control |
| 12/13/2001 | US20010051157 Therapeutic/cosmetic formulation for therapeutical treatment or care of sensitive human skin, hair, mucous membrane, nails and/or the scalp comprises a calcitonin gene related peptide (CGRP) antagonist and a carrier, diluent or vehicle |
| 12/13/2001 | US20010051140 Method for manufacturing pure guar meal |
| 12/13/2001 | US20010051139 Therapy for skin disorders |
| 12/13/2001 | US20010051134 Effervescent vitaceutical compositions and related methods |
| 12/13/2001 | US20010050242 Weight-specific elixir dosage calculator |
| 12/13/2001 | EP1143954A3 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells |
| 12/13/2001 | EP1143806A3 Method for increasing pet activity |
| 12/13/2001 | DE10127936A1 New organophosphorous-substituted hydroxamic acid compounds, useful as pre- or post-emergence selective herbicides in crops such as rice |
| 12/13/2001 | DE10127922A1 New organophosphorous-substituted hydroxamic acid compounds, useful as pre- or post-emergence selective herbicides in crops such as rice |
| 12/13/2001 | DE10101324C1 New 1-(dimercaptoalkyl)-quinazoline-2,4(1H,3H)-diones, are stable matrix metalloproteinase inhibitors useful e.g. for treating rheumatism, tumor metastasis or sunburn |
| 12/13/2001 | DE10027968A1 Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients |
| 12/13/2001 | DE10027875A1 Composition useful for the treatment of skin disorders e.g. acne comprises lipoic acid, its derivative or salt having an excess of (R)-enantiomer |
| 12/13/2001 | DE10027170A1 Humanes PEM als Target für die Fertilitätskontrolle Human PEM as a target for fertility control |
| 12/13/2001 | DE10026937A1 Agents for prophylaxis and therapy of benign prostatic hypertrophy, comprising phytoestrogens, selective estrogen receptor modulators, antiestrogens, estriol, soybean extracts or isoflavones |
| 12/13/2001 | CA2700312A1 An improved method for extracting cocoa procyanidins |
| 12/13/2001 | CA2416868A1 Identification and use of molecular markers indicating cellular reprogramming |
| 12/13/2001 | CA2414076A1 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 12/13/2001 | CA2413906A1 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | CA2412326A1 Stabilized hmg-coa reductase inhibitor pharmaceutical compositions |
| 12/13/2001 | CA2412026A1 Immunostimulatory rna/dna hybrid molecules |
| 12/13/2001 | CA2411859A1 Novel oxazolidinone derivatives and a process for the preparation thereof |
| 12/13/2001 | CA2411596A1 Therapeutic agents - ii |
| 12/13/2001 | CA2411575A1 Immunostimulatory oligodeoxynucleotides |
| 12/13/2001 | CA2411564A1 Method of treating pain using nalbuphine and opioid antagonists |
| 12/13/2001 | CA2411536A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | CA2411396A1 Hmg coa reductase inhibitors for promoting angiogenesis |